Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from PYC Therapeutics Limited ( (AU:PYC) ).
PYC Therapeutics Limited has received approval from the Safety Review Committee to escalate dosing in the clinical trial of its drug candidate PYC-003 for Polycystic Kidney Disease. This approval marks a significant step in the Single Ascending Dose study, allowing the company to proceed to the second cohort, and is part of a broader strategy to advance towards a registrational trial aimed at supporting a New Drug Application.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for patients with genetic diseases who currently have no available treatment options. The company is engaged in three clinical-stage drug development programs, including PYC-003, which targets the underlying cause of Polycystic Kidney Disease (PKD).
Average Trading Volume: 729,296
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$804.9M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.